Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stella

Recruiting

Back to Carcinoma, Renal Cell trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(3 sites)

United States

Washington University in St. Louis, St Louis, Missouri

University of Texas - MD Anderson Cancer Center, Houston, Texas

Sweden

Karolinska University Hospital, Stockholm

Key details

Phase

Safety & dosing

Sponsor

Oncorena AB

Enrollment target

~75 participants

Started

August 2023

Primary completion

December 2027

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov